Simpler stomach bug treatment on the horizon?

NCT ID NCT06977841

Completed Disease control Sponsor: Zhongshan Hospital (Xiamen), Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested different combinations of the acid-blocker tegoprazan with antibiotics to treat H. pylori, a common stomach infection. 640 adults who had never been treated before received one of several drug regimens for 14 days. The goal was to see which combination worked best with the fewest side effects, aiming to simplify treatment and reduce antibiotic resistance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tegoprazan (a stomach acid blocker) combined with antibiotics (amoxicillin or tetracycline)
What this could lead to: If successful, this could lead to simpler, better-tolerated treatment regimens for H. pylori infection, reducing side effects and antibiotic resistance.
What could go wrong: This is a completed trial, but results are not yet published. The new drug combinations may not be more effective than current standard treatments, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVERSE REACTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVERSE REACTION HELICOBACTER PYLORI ERADICATION HIGH-DOSE DUAL THERAPY

Contacts and locations

Locations

Zhongshan Hospital (Xiamen), Fudan University

Xiamen, Fujian, 361015, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.